84 results on '"de Wreede, Liesbeth C."'
Search Results
2. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?
3. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
4. Estimating distribution of length of stay in a multi-state model conditional on the pathway, with an application to patients hospitalised with Covid-19
5. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party
6. Handling missing covariate data in clinical studies in haematology
7. What is relative survival and what is its role in haematology?
8. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry
9. Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions
10. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
11. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
12. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis
13. The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
14. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
15. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
16. Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT
17. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
18. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study
19. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
20. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
21. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling.
22. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT.
23. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.
24. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion
25. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation—a phase I/II study
26. Risk factors for graft-versus-host- disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
27. Haplotype reconstruction for genetically complex regions with ambiguous genotype calls: Illustration by the KIR gene region.
28. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT.
29. Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation
30. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
31. Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting
32. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
33. Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status
34. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
35. Joint models quantify associations between immune cell kinetics and alloimmunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion.
36. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response
37. Short‐term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia
38. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
39. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
40. Multiple imputation for cause-specific Cox models: Assessing methods for estimation and prediction.
41. A dialogue on the use of arithmetic in geometry: Van Ceulen’s and Snellius’s Fundamenta Arithmetica et Geometrica
42. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models
43. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study
44. Benchmarking survival outcomes: A funnel plot for survival data.
45. Integrating relative survival in multi-state models—a non-parametric approach.
46. The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed.
47. Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice.
48. Personalized Decision Making on Genomic Testing in Early Breast Cancer: Expanding the MINDACT Trial with Decision-Analytic Modeling.
49. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
50. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.